Pharma

Zydus, Sunshine Healthcare form JV for pharma manufacturing in Sri Lanka

Zydus Lifesciences and Sri Lanka's Sunshine Healthcare on Friday announced the setting up of a joint venture with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in the island nation. The company has entered into a share subscription and shareholders' agreement (SSSHA) with Sunshine Healthcare Lanka Ltd (Sunshine) and Zydus Sunshine Lifesciences (Pvt) Ltd (Zydus Sunshine), Zydus Lifesciences said in a regulatory filing. Under the SSSHA, Zydus Lifesciences will subscribe 50 per cent of the total paid-up equity share capital of Zydus Sunshine for up to USD 5 million in one or more tranches, it added. Zydus Sunshine will set up a manufacturing facility in Horana Export Processing Zone in Sri Lanka to manufacture pharmaceutical products, which will strengthen local production and reduce import dependence, the filing said. This will improve access to high-quality medicines while supporting national supply chain resilience, it ...

Hyderabad firm builds over ₹400 crore pharma biz, without a factory

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

Zaynich antibiotic: How Wockhardt created India's first FDA-approved drug | Pharma Industry

For decades, India excelled at making affordable generic medicines. But creating a brand-new drug from scratch remained a rare achievement. Now, Wockhardt has made history with Zaynich

Cancer drug shortage: Drugmaker Naprod seeks one-time price hike

Says higher import duties, regulatory hurdles have made chemo drugs' production unviable

Indian drugmakers deepen US bets despite decline in pharma exports

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

HAB Pharma targets ₹3,000 crore revenue by 2030 after merger deal

HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal

India joins weight-loss drug race, but affordability remains a concern

India is in the race for a new class of weight-loss drugs, but the question is: Will they be affordable?

Sun Pharma bets on Organon front-end to drive global growth, efficiencies

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Will AI Change Healthcare Forever? Future of India’s Pharma Shift

In this exclusive conversation with Business Standard, Sujit Paul, CEO of Zota Healthcare and the driving force behind DavaIndia, shares bold views on the future of healthcare

Cohance Lifesciences appoints Umang Vohra as chairman, CEO; Sharma exits

Pharma veteran Umang Vohra to lead Advent-backed Cohance Lifesciences as chairman and CEO, succeeding Vivek Sharma amid efforts to revive growth and address regulatory challenges

Q4 Earnings Outlook: IT, Auto, Pharma, FMCG, Metals — What to expect | Business News | Share market

India Inc heads into the Q4 FY26 earnings season navigating a complex mix of geopolitical tensions, uneven demand trends, and cost pressures.

Everstone invests $270 mn in Apothecon-Navinta specialty pharma platform

The deal creates Apothecon Group, a specialty pharma company focused on regulated markets in the US, Europe and India, with plans to expand its pipeline, footprint and acquisitions

Aurobindo Pharma sets April 12 as record date for ₹800 crore buyback

Company to repurchase up to 54.24 lakh shares at Rs 1,475 apiece through tender offer route, with promoters also eligible to participate in the buyback

Effective oversight: Safety crucial for success of weight-loss drugs

According to the National Family Health Survey 2019-21, 24 per cent of Indian women and 23 per cent of Indian men are overweight

Eli Lilly banks on tirzepatide's clinical edge as GLP-1 generics loom

Lilly positions tirzepatide as a clinically superior option as semaglutide patent expiry triggers a wave of generics, intensifying competition in India's diabetes and obesity market

Aurobindo arm launches Pomalidomide generic in US, adds to oncology line

Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio

Indian MSME drugmakers likely to focus on Brazil as next growth market

India-Brazil pharma meet highlights Brazil's growing role as a priority market for Indian MSME drugmakers, driven by rising exports, regulatory engagement and demand for specialty medicines

CDSCO eases NOC norms to speed up clinical research and pharma exports

India's drug regulator is withdrawing export NOC requirements for SRA markets and easing other low-risk approvals, even as it strengthens oversight of manufacturing quality

Pharma exports rise 9.4% in FY25; industry eyes double-digit growth

The commerce ministry on Saturday said the country's pharma exports grew 9.4 per cent in 2024-25 to USD 30.47 billion and the industry is aiming for a double-digit expansion in 2026-27. Issues pertaining to pharmaceuticals exports were discussed between the government officials and industry during Chintan Shivir in Ahmedabad. The sector, currently valued around USD 60 billion, is projected to reach USD 130 billion by 2030. India ranks third globally by volume, with medicines exported to over 200 markets, and more than 60 per cent of exports destined for stringent regulatory markets. The US accounts for 34 per cent and Europe for 19 per cent of India's pharmaceutical exports. "The interaction underlined the government's focus on enabling conditions for sustained export acceleration, with industry indicating readiness to target double-digit growth in 2026-27," it said. It added that exporters were also apprised of opportunities arising from recent trade engagements with key partner

Indian pharma may face muted US growth in FY27 on gRevlimid pressure

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry